Ridinilazole for the treatment of Clostridioides difficile infection

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

(2018) L Clifford McDonald et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

(2018) David R Snydman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis

(2018) Tumas Beinortas et al.   LANCET INFECTIOUS DISEASES

Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection

(2018) Charles Burdet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals

(2018) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial

(2017) P Daley et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

(2017) Richard J Vickers et al.   LANCET INFECTIOUS DISEASES

Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection

(2017) Vicente Boix et al.   Open Forum Infectious Diseases

Community Environmental Contamination of Toxigenic Clostridium difficile

(2017) M Jahangir Alam et al.   Open Forum Infectious Diseases

Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection

(2016) Eugénie Bassères et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Surotomycin versus vancomycin forClostridium difficileinfection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial

(2016) Christine H. Lee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire

(2016) Kevin W. Garey et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study

(2016) D.N. Shah et al.   JOURNAL OF HOSPITAL INFECTION

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection

(2015) Thomas Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators

(2015) Jane Freeman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

(2015) Richard Vickers et al.   BMC INFECTIOUS DISEASES

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic–industrial partnership

(2015) John Mann et al.   MedChemComm

In VivoAssessment of SMT19969 in a Hamster Model of Clostridium difficile Infection

(2014) William Weiss et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Real-Time Polymerase Chain Reaction Detection of Asymptomatic Clostridium difficile Colonization and Rising C. difficile–Associated Disease Rates

(2014) Hoonmo L. Koo et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model

(2014) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999–2007

(2012) Aron J. Hall et al.   CLINICAL INFECTIOUS DISEASES

Burden of Clostridium difficile on the Healthcare System

(2012) Erik R. Dubberke et al.   CLINICAL INFECTIOUS DISEASES

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Fidaxomicin inhibits toxin production in Clostridium difficile

(2012) F. Babakhani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study

(2011) Sahil Khanna et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals

(2011) Becky A. Miller et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection

(2011) K. W. Garey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY